Fact Summary
argenx SE is a Belgium/Netherlands-based immunology company whose lead franchise is the autoimmune disease treatment VYVGART/VYVGART Hytrulo (efgartigimod). The company recorded full fiscal year 2025 product net sales of $4.15B (+90% year-over-year) and achieved its first full-year operating profit of $1,053.8M in 2025. Second-quarter 2026 product net sales continued the growth trend at $1.516B (+60% year-over-year), and on 2026-08-17 the company announced that the Phase 3 ALKIVIA trial in myositis met its primary endpoint. On the same day, the stock rose approximately 16% intraday from the reference-date (2026-08-14) closing price. At the 2026-05-06 Annual General Meeting, a leadership change took place in which founder Tim Van Hauwermeiren became Chairman of the Board and Karen Massey became the new Chief Executive Officer.
Price-Change Context Note
The reference-date (2026-08-14) closing price was $851.29, down -0.66% from the previous day; however, following the Phase 3 ALKIVIA trial results announced on the next trading day, 2026-08-17, the stock surged intraday, so the market reaction was confirmed at a point after the reference date. Within the recent six-month period, the FDA's expanded label approval for gMG across all serotypes (2026-05-08) and the CEO transition (2026-05-06) occurred in close proximity to one another.
Business Overview
The lead product VYVGART/VYVGART Hytrulo (efgartigimod alfa) is approved for adult generalized myasthenia gravis (gMG, all serotypes), chronic inflammatory demyelinating polyneuropathy (CIDP, worldwide), and primary immune thrombocytopenia (ITP, Japan). On 2026-05-08 the FDA approved an expanded VYVGART label covering all gMG serotypes, including seronegative patients (GlobeNewswire, 2026-05-08).
| Timing | Pipeline Event |
|---|---|
| 2026-08-17 | ALKIVIA (myositis) Phase 3 primary endpoint met, results announced — Complete |
| 4Q26 | empasiprubart (ARGX-117) MMN registrational trial EMPASSION results (E, per company disclosure) |
| 1H27 | ITP registrational trial ADVANCE-NEXT results (E) |
| 2H27 | Sjögren's syndrome UNITY, empasiprubart CIDP EMVIGORATE/EMNERGIZE results (E) |
| 2027 | VYVGART SC auto-injector launch (E) |
5-Year Financial Trend (2021-2025, USD)
| Year | Product Net Sales | Operating Income/(Loss) | Net Income/(Loss) | Total Assets | Total Equity |
|---|---|---|---|---|---|
| 2021 | $0 | $(348.7)M | $(408.3)M | $2,850.3M | $2,534.2M |
| 2022 | $400.7M | $(720.3)M | $(709.6)M | $3,134.3M | $2,813.7M |
| 2023 | $1,190.8M | $(425.0)M | $(295.1)M | $4,542.0M | $4,097.5M |
| 2024 | $2,185.9M | $(21.7)M | $833.0M | $6,202.5M | $5,498.3M |
| 2025 | $4,151.3M | $1,053.8M | $1,292.0M | $8,682.7M | $7,323.1M |
Product net sales grew roughly 10.4x over three years, from $400.7M in 2022 to $4,151.3M in 2025. Operating income/(loss) improved from a peak loss of $(720.3)M in 2022, narrowing over time before turning to a first-ever full-year operating profit of $1,053.8M in 2025. The 2024 net income of $833.0M, despite an operating loss of $(21.7)M, was attributable to a $748M income tax benefit — the point of substantive operating profitability was actually 2025.
Competitive Landscape
| Company | Product | Mechanism | gMG Approval Date | FY2025 Revenue |
|---|---|---|---|---|
| argenx | VYVGART/VYVGART Hytrulo | FcRn inhibitor | 2021-12 (US) | $4.15B |
| UCB | Rystiggo | FcRn inhibitor | 2023-06 (US) | €332M |
| UCB | Zilbrysq | Complement (C5) inhibitor | 2023-10 (US) | €217M |
| AstraZeneca (Alexion) | Ultomiris | Complement (C5) inhibitor | Previously approved | Not available (reported at consolidated company level) |
| Johnson & Johnson | Imaavy | FcRn inhibitor | 2025 (US) | Not available |
| Amgen | UPLIZNA | Anti-CD19 B-cell depleting antibody | 2026-02 (EU) | Not available |
The gMG (generalized myasthenia gravis) market is led by argenx and UCB, with Amgen, Regeneron, AstraZeneca (Alexion), and Johnson & Johnson also competing (BioSpace, secondary source). Immunovant's second-generation FcRn inhibitor IMVT-1402 has expanded-indication trial results scheduled for 2027 (FierceBiotech).
Valuation
The above multiples were recalculated by applying the system-verified closing price of $851.29 (2026-08-14) to per-share metrics from stockanalysis.com. Using the intraday price following the 2026-08-17 ALKIVIA results announcement ($991.33), PER is approximately 30.83x, P/B approximately 6.28x, and P/S approximately 9.95x; however, since these reflect a different trading day than the reference date, they are provided for direct-comparison reference only (stockanalysis.com, 2026-08-17 12:26pm ET). A secondary qualitative assessment notes that ARGX's PER is higher than the broader biotech sector average (approximately 25.8x) but lower than its peer-group average (approximately 67.5x).
Governance & Capital Structure
| Date | Event |
|---|---|
| 2026-01-05 | First disclosure of CEO succession plan |
| 2026-05-06 | Annual General Meeting (AGM) — Karen Massey appointed CEO, Tim Van Hauwermeiren transitions to Chairman of the Board |
| 2026-08-03 | Extraordinary General Meeting (EGM) convened (director appointment agenda item) |
| 2026-09-17 | Extraordinary General Meeting (EGM) scheduled to be held (Amsterdam) |
At the 2026-05-06 Annual General Meeting, a leadership succession took place in which founder and then-CEO Tim Van Hauwermeiren became Chairman of the Board, and then-Chief Operating Officer Karen Massey became the new CEO. Over the same period, T. Rowe Price's reported ownership stake steadily declined from 8.2% on 2025-06-30 to 4.3% on 2026-06-30, while FMR LLC (Fidelity) has maintained its position as the largest reported shareholder at 8.7% as of 2026-03-31.
Fund Flows & Ownership
As of the 2026-07-31 report, short interest as a percentage of float was 2.19%, down 13.30% from the prior report (2026-07-15, 2.50%) (MarketBeat, republishing FINRA data). As of Q2 2026 13F filings, total institutional ownership stood at 60.32%, with the largest holders being FMR LLC ($3.46B), T. Rowe Price ($3.19B), and Janus Henderson ($1.42B), in that order. As a foreign private issuer, argenx SE is exempt from US Section 16 Form 4 filing requirements, so insider trading activity cannot be tracked through that channel.
Macro Environment
| Factor | Current Value (as of reference date) | Impact (Direction · Magnitude) |
|---|---|---|
| US 10-Year Treasury Yield | 4.69% (2026-08-17) | Neutral to slightly negative, medium magnitude |
| US Federal Reserve Policy Rate | 3.50-3.75% (held on 2026-07-29) | Slightly negative, low magnitude |
| US Dollar Index (DXY) | approx. 99.5 (2026-08-10) | Limited/mixed, low magnitude |
| EUR/USD | 1.1564 (2026-08-16) | Slightly negative (cost side), low magnitude |
| Nasdaq / Biotech (XBI) | Nasdaq 26,729.16 · XBI $157.40 (2026-08-14) | Partially correlated, idiosyncratic momentum dominant |
| US IRA Drug Price Negotiation | VYVGART not included in 2026 selected drug list | Neutral (near term), low magnitude |
Having turned GAAP-profitable in 2025 with the majority of revenue generated in the US (USD), argenx has a comparatively weak transmission channel for the valuation pressure that high interest rates typically place on loss-making growth biotechs. Under the 13-year exemption period following first biologic approval, VYVGART's inclusion in IRA drug price negotiations would not occur until after 2034, making near-term policy risk low. In practice, actual price movements are dominated by individual pipeline events — such as the 2026-08-17 ALKIVIA Phase 3 results — rather than sector beta (Benzinga, 2026-08-18).
Recent Events
| Date | Event |
|---|---|
| 2026-08-17 | Phase 3 ALKIVIA (myositis) primary endpoint met, results announced |
| 2026-08-06 | Tender offer for Forte Biosciences shares commenced ($77.00 per share, cash) |
| 2026-08-03 | Extraordinary General Meeting convened (scheduled for 2026-09-17) |
| 2026-07-27 | Forte Biosciences acquisition agreement announced (adds FB102 to pipeline) |
| 2026-07-23 | First-half (H1) 2026 results announced — Q2 net sales $1.5B (+60% YoY) |
| 2026-05-08 | FDA approved expanded VYVGART label covering all gMG serotypes |
| 2026-05-06 | Annual General Meeting — CEO transition (Karen Massey appointed) |
| 2026-02-26 | Full fiscal year 2025 results announced — revenue $4.2B (+90%), first full-year operating profit |
Risk Factors (Factual)
| Category | Summary Fact |
|---|---|
| Revenue concentration | The majority of FY2025 revenue came from the single VYVGART franchise; subsequent pipeline products have not yet contributed revenue |
| Intensifying competition | UCB, J&J, Amgen, AstraZeneca (Alexion), and others are entering the gMG market via FcRn/complement inhibition mechanisms; Immunovant's second-generation FcRn inhibitor trial results are scheduled for 2027 |
| Patents | The base efgartigimod patent expires in 2036 in the US and in 2034 in many other countries (secondary source) |
| Regulation/pricing | VYVGART's inclusion in IRA drug price negotiations would not occur until after 2034, so near-term risk is low, but market exclusivity is not absolute given the potential approval of competing products in the same indication |
| Clinical pipeline | ALKIVIA (myositis) was resolved with results announced on 2026-08-17; others — empasiprubart MMN (4Q26), ITP ADVANCE-NEXT (1H27), Sjögren's UNITY (2H27) — remain pending results |
| Governance | CEO transition on 2026-05-06 (management succession); the 2026 AGM approved authorization to issue new shares up to 10% of shares outstanding (potential dilution) |
| Currency | Foreign exchange exposure from a Belgium-based EUR cost base versus a US-centric USD revenue structure; macro impact assessed as limited/mixed |
| Valuation | Following the 2026-08-17 ALKIVIA results announcement, the stock rose approximately 16% intraday, adding further gains on top of multiples that already reflect substantial growth expectations |
Thematic Relevance
Fact Highlights
This is not investment advice. FomoLog provides factual summaries and post-hoc price-change context only. Investment decisions and their outcomes are solely the responsibility of the investor.
Source: Generated by FomoLog Agent · Data sources: Korea Exchange · NASDAQ · DART · SEC EDGAR